Angiotensin II type 1 receptor blockade with 80 and 160 mg valsartan in healthy, normotensive subjects

Background: An 80-mg dose once or twice daily is the dose of valsartan freq uently administered for treatment of hypertension. The target dose selected for the Val-HeFT trial in patients with chronic heart failure is 160 mg tw ice daily. The level and time course of angiotensin 11 type I (AT(1))-recep tor blockade achieved by 160 mg valsartan have not been reported. Methods and Results: Seven normotensive healthy subjects were assigned in r andom order to receive a single dose of placebo, 80 mg valsartan, and 160 m g valsartan at 7- to 10-day intervals. AT(1)-receptor blockade level (%) wa s determined by the pressure response to administration of exogenous angiot ensin 11. The pressure response to angiotensin 11 was measured at baseline and 2, 6, 12, and 24 hours after oral administration of placebo, 80 mg vals artan, and 160 mg valsartan. Eighty and 160 mg valsartan resulted in a sign ificant and similar level of AT(1)-receptor blockade at 2 and 6 hours compa red with placebo. The 160-mg dose resulted in a significantly greater level of AT(1)-receptor blockade than 80 mg at 12 and 24 hours. Conclusions: During the first 6 hours after oral administration of 80 and 1 60 mg valsartan the level of AT(1) -receptor blockade is similar. However, only 160 mg valsartan provides sustained AT(1)-receptor blockade over 24 ho urs.